Following the subsequent rounds of treatment, the release of tumor antigen leads to the cross-priming and the generation of tumor antigen-specific CD8+ T cells, which are likewise able to kill tumor cells (Fig. 4). The gene discussed is CD8A; the disease is neoplasm.